On April 13, 2026 Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lu will participate in an educational session titled "Engineered NK Cells: From Innate Immunity to Clinical Innovation." The session will highlight advances in the development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader potential for Logic Gates to address a wide range of unmet needs in oncology.

Presentation Details:

Session Title: Engineered NK Cells: From Innate Immunity to Clinical Innovation
Session Type: Educational Session
Presenter: Timothy Lu, Co-Founder & CEO, Senti Biosciences
Date: Friday, April 17, 2026
Time: 3:00 – 4:30 PM PT
Location: AACR (Free AACR Whitepaper) Annual Meeting 2026, San Diego, CA
"We are honored to contribute to this important educational session at AACR (Free AACR Whitepaper)," said Dr. Lu. "Our Logic-Gated cell therapies selectively kill cancer cells while protecting healthy cells. Enhanced therapeutic windows from Logic Gates enable the treatment of cancers for which conventional single-target biologics, such as T cell engagers and antibody-drug conjugates, and conventional single-target cell therapies are unable to perform. We look forward to sharing insights from our recent SENTI-202 clinical trial results in relapsed/refractory acute myeloid leukemia and other applications of our Logic Gates to improve precision and efficacy for cancer therapies."

The AACR (Free AACR Whitepaper) Annual Meeting is one of the leading global conferences for cancer research, bringing together scientists, clinicians, and industry leaders to discuss the latest advances in cancer science and medicine. For more information, please visit the conference website.

(Press release, Senti Biosciences, APR 13, 2026, View Source [SID1234664341])

On April 13, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that an oral podium presentation featuring colorectal cancer data for the company’s NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting April 17-22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A focus of this year’s data is the introduction of a new NeXT Personal MRD test option, Real-Time Variant Tracker, a first-of-its-kind feature in tumor-informed clinical MRD testing, designed to longitudinally track therapy resistance mutations.

"We are thrilled to present the first NeXT Personal data on the Real-Time Variant Tracker. The AACR (Free AACR Whitepaper) data highlights how tracking therapy resistance mutations like ESR1 during MRD testing has the potential to inform patient management once cancer recurrence is detected," said Dr. Richard Chen, President and Chief Medical Officer at Personalis. "In addition, the data presented at AACR (Free AACR Whitepaper) further reinforces that ultrasensitive ctDNA detection with NeXT Personal can impact how colorectal cancer is monitored and managed. Both of these studies are examples of our unwavering commitment to innovation to drive better outcomes for patients."

Presentations at AACR (Free AACR Whitepaper) highlighting the use and clinical impact of the ultrasensitive NeXT Personal MRD test include:

Oral Podium Presentation: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction.
Focus: Highlights the ultrasensitive ctDNA detection of NeXT Personal for predicting and tracking response to neoadjuvant immunotherapy in CRC patients.
Time: April 20, 2026, 2:35 PM–2:45 PM
Location: Room Hall H – Ground Level

Poster Presentation: Monitoring ESR1 and other mutations linked to resistance with a tumor-informed MRD test: Analytical validation and real world data.
Focus: Presents the analytical validation and real-world case studies of the new Real-Time Variant Tracker feature of NeXT Personal enabling detection of resistance and other clinical mutations during MRD testing.
Time: April 20, 2026, 9:00 AM–12:00 PM
Location: Section 46, Poster #2588

Poster Presentation: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data.
Focus: A deep analysis of the real-world clinical performance of NeXT Personal across a large patient cohort. The data highlights the ability for NeXT Personal to consistently achieve ultrasensitive ctDNA detection levels below 100 parts per million (ppm) and 10 ppm, across a diverse set of solid tumor types, stages, and challenging real-world testing conditions.
Time: April 20, 2026, 2:00 PM–5:00 PM
Location: Section 45, Poster #8225

Poster Presentation: Ultrasensitive ctDNA monitoring predicts early response of immunotherapy in recurrent metastatic non-small cell lung cancer.
Focus: Demonstrates the performance of NeXT Personal for predicting relapse and outcomes in advanced NSCLC patients receiving immunotherapy.
Time: April 20, 2026, 2:00 PM–5:00 PM
Location: Section 45, Poster #3851

(Press release, Personalis, APR 13, 2026, View Source [SID1234664340])

On April 13, 2026 Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, California. The presentations highlight Leukogene’s MHC class II engager lead development candidates in acute myeloid leukemia (AML) and pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster is titled "MHC class II engager immunotherapy for the treatment of acute myeloid leukemia (Poster Board #24, Poster #5552)".

The second poster is titled "MHC class II targeted immunotherapy in the treatment of pancreatic cancer (Poster Board #23, Poster #5551)".

These presentations will focus on an MHC class II-directed strategy in hematological cancers and solid tumors designed to recruit and activate anti-tumor immune cells, with the goal of converting immunologically "cold" tumors into more inflamed, "hot" lesions that respond better to immunotherapy. The company has developed a robust preclinical data package with evidence of single agent and combination efficacy, underscoring the potential of this approach to address a major unmet need in aggressive malignancies.

Both posters will be presented during the Immunology poster session titled "Bi- and Tri-Specific Antibody Therapies" on April 21, 2026, from 2:00 p.m. to 5:00 p.m. Pacific Time in Poster Section 6 at the San Diego Convention Center.

"Acute myeloid leukemia and pancreatic cancer remain among the most lethal and treatment‑resistant cancers, and there is a pressing need for more effective and durable therapies," said Sandeep Gupta, Ph.D., Chief Executive Officer of Leukogene Therapeutics. "These AACR (Free AACR Whitepaper) presentations emphasize the potential of our MHC class II-engager platform to reshape immune responses in both hematologic and solid tumors, and they represent an important step toward bringing new immunotherapy options to patients with limited choices."

(Press release, Leukogene Therapeutics, APR 13, 2026, View Source [SID1234664339])

On April 13, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will present eight scientific posters and one oral presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026 (booth #1537).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive AI-based analysis, and help translate findings into clinically relevant insights. By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application, with the potential to enable cutting-edge oncology therapy development and commercialization.

"Bringing together lab and clinical data is becoming foundational to modern oncology research," said Tony Zook, CEO at NeoGenomics. "Our collaborations with biopharma partners have allowed us to develop compelling research that we’re proud to present at AACR (Free AACR Whitepaper), showcasing how these insights can directly enhance therapy development and create optionality for providers and patients."

Presentations at AACR (Free AACR Whitepaper) include:

Oral presentation (Clinical Trials Mini Symposium: Focus on ctDNA): Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial
Monday, April 20, at 2:30–4:30 PM
Poster #1106: Rapid identification of comprehensive multi-omic protein and RNA biomarkers on a single FFPE tissue section using a novel integrated nCounter workflow
Sunday, April 19, at 2:00–5:00 PM | Section 43
Poster #1224: Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment
Sunday, April 19, at 2:00–5:00 PM | Section 47
Poster #1456: Paletrra AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training
Monday, April 20, at 9:00 AM–12:00 PM | Section 4
Poster #1993: Real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies
Monday, April 20, at 9:00 AM–12:00 PM | Section 23
Poster #4162: AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens
Tuesday, April 21, at 9:00 AM–12:00 PM | Section 3
Poster #8493: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
Tuesday, April 21, at 9:00 AM–12:00 PM | Section 20
Poster #6674: Metabolic reprogramming in advanced renal tumors contributes to a dysfunctional immune response and immune exhaustion within the tumor microenvironment
Tuesday, April 21, at 2:00–5:00 PM | Section 48
Poster #7263: Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing
Wednesday, April 22, at 9:00 AM–12:30 PM | Section 21
Attendees interested in learning more about NeoGenomics’ clinical and genomics insight capabilities can connect with the team onsite at booth #1537.

(Press release, NeoGenomics Laboratories, APR 13, 2026, View Source [SID1234664338])

On April 13, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported Allogene Therapeutics’ (NASDAQ: ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive patients treated with cema-cel achieved MRD clearance. In addition, at the Day-45 MRD assessment, plasma ctDNA levels decreased from baseline by a median of 97.7% in the cema-cel arm compared to a 26.6% median increase in the observation arm, suggesting molecular disease progression due to lack of intervention. These findings provide early evidence that cema-cel may help prevent or delay clinical relapse for LBCL patients with MRD.

While standard 1L chemoimmunotherapy (e.g., R-CHOP) is effective for most patients in achieving remission, approximately 30% will experience relapse. MRD assessment can identify such relapse before it shows up on imaging.1

ALPHA3 is the first MRD-guided randomized controlled trial in LBCL. The study is designed to assess whether treatment with an allogenic CAR T product can eliminate residual disease and potentially prevent recurrence. The study identifies high-risk patients using Natera’s CLARITYTM MRD assay, which leverages Natera’s patented phased variant MRD technology.

The interim analysis evaluated MRD clearance following treatment at a protocol-defined data cutoff. This represents another critical application for Natera’s MRD technology, providing a meaningful interim endpoint for assessing drug efficacy.

"MRD status following frontline therapy has emerged as one of the strongest predictors of relapse in LBCL, and the ALPHA3 study and cema-cel could be transformative for patients with lymphoma," said David Kurtz, M.D., Ph.D., senior vice president & chief scientific officer, Hematology Franchise at Natera. "Pairing our ultra-sensitive phased variant MRD technology with cema-cel, pending the outcome of ALPHA 3 study, creates an actionable solution for patients who test positive for MRD at the end of 1L treatment."

Allogene will host a conference call and webcast today at 5:30 a.m. PT / 8:30 a.m. ET to discuss the interim futility analysis. The webcast will be made available at www.allogene.com under the Investors tab in the News and Events section.

(Press release, Natera, APR 13, 2026, View Source [SID1234664337])